# A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

> **NCT04488133** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 46 (actual)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** Nusinersen

## Key facts

- **NCT ID:** NCT04488133
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-10-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488133, "A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04488133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*